Jump to:

PHARMASEAL hero image

PHARMASEAL

Follow

We help biopharmaceutical companies run and manage their clinical trials using our cloud B2B software.

104%
 - 
Funded 13 Nov 2020
£500,001 target
£522,312 from 588 investors
More
Less

Business overview

Location NOTTINGHAM, United Kingdom
Social media
Website www.pharmaseal.co
Sectors Healthcare Mixed Digital/Non-Digital B2B
Company number 09993255
Incorporation date 8 Feb 2016
More
Less

Investment summary

Type Equity
Valuation (pre-money) £1M
Equity offered 33.29%
UK tax relief

EIS

More
Less

Business highlights

  • Proof of concept June 2017
  • First Market Release of Engility® Trial Management June 2019
  • First customer signed up October 2019
  • PHARMASEAL wins East Midlands Medilink Start Up award Dec 2019
More
Less

Key features

  • Secondary Market
  • Nominee investment min. £12.00 +

Idea

Introduction

PHARMASEAL is a software company that is disrupting how clinical trials are managed in its mission to bring new medicines to market faster. Engility® is a new cloud B2B platform, designed for the thousands of global SME companies developing new drugs and medical devices. Typically companies use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Engility® simplifies control by providing a single management platform allowing information to be centralised and accessed from a single platform. With Engility®, companies and suppliers can collaborate, improving the productivity of the supply chain and as a result, their clinical trials. SME companies are critical in developing new medical innovations. Engility® can transform the productivity of the SME sector through the digitisation of processes. Join us in reimagining how future clinical trials are managed.

Substantial accomplishments to date

- February 2016: PHARMASEAL created (formerly known as DCI Consulting)

- October 2016: Started company operations (development), bootstrapped with a Director's loan

- June 2017: Proof of concept completed

- Dec 2017: First seed funding round raised to advance the proof of concept to a minimum viable product (MVP)

- January 2019: MVP completed and company publicly launched with website, advertising and marketing

- February 2019: Second seed funding round raised for final market release and commence commercialisation phase

- June 2019: Market ready Engility® Clinical Trial Management System (CTMS) launched

- October 2019: First customer won(US outcomes research company)

- December 2019: PHARMASEAL wins UK East Midlands "Start Up Company of the Year"

- January 2020: Successfully completed pilot evaluation with UK based medical imaging company

- February 2020: Inside sales function hired to support commercialisation

- March 2020: Added 2nd major business capability (module) electronic trial master file (eTMF) to the Engility® platform, validating the "integrated management" approach for a unified governance system

- July 2020: US medical device company commences evaluation

- August 2020: Crowdfunding campaign launched

Monetisation strategy

PHARMASEAL is a software B2B business selling to pharmaceutical, biotechnology, medical device and contract research organisations engaged in running clinical trials for the approval of new medicines and medical devices. The primary source of revenue is a SaaS software subscription license to use the Engility® platform. Typical contracts will be for a 3-year term license with annual payment in advance. Software subscription will typically generate 80% of the company revenue. Secondary sources of revenue are services associated with the software implementation such as training and implementation services and expected to comprise 20% of the company's revenue. The company has created two product capabilities - a base module Clinical Trial Management System (CTMS) and an optional electronic trial master file (eTMF) module. The company determines the band of charge a customer will fall into based on its industry segment and number of active clinical trials that are run by the organisation

Use of proceeds

The funds raised will support 6-9 months of operational cash flow and support the first stage of commercialisation and disruptive product development. PHARMASEAL is targetting the USA/EU for the first cohort of B2B customer wins. Developing case studies from these initial sales will demonstrate value and accelerate marketing & sales. The utilisation of funds is split between the following activities:

- Commercialisation & Marketing: 31%

- Product Development: 49%

- IT Infrastructure: 13%

- Admin/Legal/Misc: 7%

Inside sales function driving lead generation will be expanded and focussed on US and EU territories respectively to attract early adopters.

Targeted Marketing supports digital advertising, trade publications, webinars and relevant conferences.

Product development is focussed on disruption by:

- Further developing the full capabilities of the 2nd product (electronic trial master file) recently added to the platform

- Enhancing general platform features (BI and Integrations)

Open an account to get access to the team members of PHARMASEAL

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for PHARMASEAL has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 1 September 2020 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £1,045,164

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Republic Europe.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Republic Europe

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Republic Europe campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Nominee investment

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Nominee investment.

Find out more

Custodian

If you invest in this Campaign, Republic Europe will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Republic Europe will not benefit from any rights under a shareholder agreement. As a result, Republic Europe will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

If available, this is an option to invest and hold shares 'directly' in the company (rather than via the Nominee investment). This option is only available to those investing over the threshold amount, which is determined by the fundraising company.

If you choose to hold your shares directly, you will be responsible for any contractual or administrative arrangements with the company you are investing in.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer or using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Republic Europe. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.

Security Token

A security token is a digital asset that represents ownership or other rights. It is a digital form of traditional investments. In the future, you may be able to trade your investment through compatible exchanges.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Republic Europe.

ContinueCancel